This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

EDAP's Ablatherm-HIFU Offers Reliable Therapy For Localized Prostate Cancer

LYON, France, Feb. 22, 2013 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today new long term data demonstrating high rates of both cancer-specific survival, and freedom from salvage therapy for patients treated with high-intensity focused ultrasound (HIFU) therapy. The study was performed by Drs. Stefan Thürroff and Christian Chaussy and evaluated the cancer control and morbidity of HIFU, in combination with transurethral resection of the prostate prior to treatment, over a 15 year period. The study was electronically published in February 2013 by the Journal of Urology, the Official Journal of the American Urological Association.

The study, titled "Evolution and outcomes of 3 MHz High intensity focused ultrasound therapy for localized prostate cancer over 15 years," examined 704 patients treated from 1995 to the end of 2009 at the Munich-Harlaching Clinic located in Munich, Germany. Within the study population, 78.5% of men had intermediate- or high-risk disease. Data showed a cancer-specific survival rate after treatment of 99% and a metastasis-free survival rate of 95%. The salvage treatment-free rates were 98% for low-risk, 72% for intermediate-risk, and 68% for high-risk disease. The overall survival of the patients in the study did not differ across risk groups and was identical to current local (Bavarian) population survival statistics.

Stefan Thüroff, M.D., Primary Investigator and Vice Chairman of the Department of Urology at the Harlaching Clinic, said, "These study results show that HIFU offers men with localized prostate cancer a standardized, reliable therapy with a low rate of perioperative co-morbidity and an absence of serious morbidity. Importantly, we found that salvage therapy was not required by 98% of low-risk patients. This outcome is extremely important from the perspective of the patient, and clearly demonstrates the extent of cancer control afforded by HIFU therapy."

Dr. Thüroff concluded, "HIFU has remained investigational because the published research on the therapy has not yet reached sufficient maturity to be considered definitive. The authors of this study concur that the collected data of 15 year outcomes may warrant the possible closing of the investigational phase of whole gland HIFU. The confidence this study provides in the ability to ablate prostate cancer may also encourage the use of focal therapy."

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs